Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:BBIO NASDAQ:KNSA NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$247.05-0.2%$232.68$153.49▼$250.74$15.44B0.41739,020 shs450,896 shsBBIOBridgeBio Pharma$69.12-1.7%$71.30$31.77▼$84.94$13.77B1.023.36 million shs1.83 million shsKNSAKiniksa Pharmaceuticals International$53.24-0.8%$49.40$25.70▼$59.87$4.13B0.17786,396 shs382,321 shsSMMTSummit Therapeutics$16.62-4.9%$18.92$13.83▼$30.98$13.56B-1.254.41 million shs6.89 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-0.19%+2.72%+6.92%+9.80%+56.26%BBIOBridgeBio Pharma-1.65%+4.52%-7.15%+1.44%+110.48%KNSAKiniksa Pharmaceuticals International-0.76%-5.79%+23.70%+11.45%+103.83%SMMTSummit Therapeutics-4.87%-1.48%-32.38%+4.27%-34.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$247.05-0.2%$232.68$153.49▼$250.74$15.44B0.41739,020 shs450,896 shsBBIOBridgeBio Pharma$69.12-1.7%$71.30$31.77▼$84.94$13.77B1.023.36 million shs1.83 million shsKNSAKiniksa Pharmaceuticals International$53.24-0.8%$49.40$25.70▼$59.87$4.13B0.17786,396 shs382,321 shsSMMTSummit Therapeutics$16.62-4.9%$18.92$13.83▼$30.98$13.56B-1.254.41 million shs6.89 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-0.19%+2.72%+6.92%+9.80%+56.26%BBIOBridgeBio Pharma-1.65%+4.52%-7.15%+1.44%+110.48%KNSAKiniksa Pharmaceuticals International-0.76%-5.79%+23.70%+11.45%+103.83%SMMTSummit Therapeutics-4.87%-1.48%-32.38%+4.27%-34.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$295.3919.57% UpsideBBIOBridgeBio Pharma 2.88Moderate Buy$88.9028.62% UpsideKNSAKiniksa Pharmaceuticals International 2.78Moderate Buy$60.8614.31% UpsideSMMTSummit Therapeutics 2.35Hold$26.0556.76% UpsideCurrent Analyst Ratings BreakdownLatest KNSA, ASND, BBIO, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026SMMTSummit Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/22/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/21/2026SMMTSummit Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderperform$7.705/19/2026BBIOBridgeBio Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$82.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$355.005/18/2026ASNDAscendis Pharma A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/18/2026KNSAKiniksa Pharmaceuticals International Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/15/2026BBIOBridgeBio Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)5/15/2026ASNDAscendis Pharma A/S EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$329.005/11/2026ASNDAscendis Pharma A/S BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$342.00 ➝ $345.005/11/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$100.00 ➝ $110.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$814.57M18.92N/AN/A$9.16 per share26.97BBIOBridgeBio Pharma$502.08M26.96N/AN/A($11.58) per share-5.97KNSAKiniksa Pharmaceuticals International$677.56M6.05$0.79 per share67.59$7.87 per share6.76SMMTSummit TherapeuticsN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6728.4923.85N/A57.87%N/A-8.37%8/6/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A276.48N/A-124.42%N/A-65.81%8/4/2026 (Estimated)KNSAKiniksa Pharmaceuticals International$59.01M$0.9059.1631.32N/A9.69%13.26%9.86%7/28/2026 (Estimated)SMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%8/10/2026 (Estimated)Latest KNSA, ASND, BBIO, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million4/30/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 million2/24/2026Q4 2025BBIOBridgeBio Pharma-$0.75-$1.00-$0.25-$1.00$150.71 million$154.18 million2/24/2026Q4 2025KNSAKiniksa Pharmaceuticals International$0.29$0.17-$0.12$0.17$200.86 million$202.13 million2/23/2026Q4 2025SMMTSummit Therapeutics-$0.22-$0.29-$0.07-$0.29$75.47 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72BBIOBridgeBio PharmaN/A1.521.48KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33SMMTSummit TherapeuticsN/A7.417.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ABBIOBridgeBio Pharma99.85%KNSAKiniksa Pharmaceuticals International53.95%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%BBIOBridgeBio Pharma14.23%KNSAKiniksa Pharmaceuticals International51.98%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableKNSAKiniksa Pharmaceuticals International22076.94 million36.95 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableKNSA, ASND, BBIO, and SMMT HeadlinesRecent News About These CompaniesHere's Why You Should Add SMMT Stock to Your Portfolio NowMay 22 at 10:31 AM | zacks.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 20 at 4:55 AM | americanbankingnews.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18, 2026 | zacks.comSummit Therapeutics (NASDAQ:SMMT) Lowered to "Sell" Rating by Wall Street ZenMay 18, 2026 | americanbankingnews.comSummit Therapeutics PLC $SMMT Stock Holdings Decreased by Vanguard Group Inc.May 11, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Upgraded at Wall Street ZenMay 10, 2026 | marketbeat.comQ2 EPS Estimate for Summit Therapeutics Boosted by AnalystMay 8, 2026 | marketbeat.comQ2 Earnings Forecast for SMMT Issued By HC WainwrightMay 7, 2026 | marketbeat.comSMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab SetbackMay 4, 2026 | zacks.comSummit Therapeutics: More Uncertainty Heading Into The ASCO PlenaryMay 4, 2026 | seekingalpha.comBuy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash RunwaysMay 4, 2026 | 247wallst.comSummit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 4, 2026 | globenewswire.comHC Wainwright Issues Pessimistic Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock PriceMay 4, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)May 3, 2026 | theglobeandmail.comSummit Therapeutics (SMMT) Receives a Rating Update from a Top AnalystMay 3, 2026 | theglobeandmail.comSMMT stock plunges on wider Q1 loss, lung cancer clinical trial updateMay 2, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Issues Earnings ResultsMay 2, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street ZenMay 2, 2026 | marketbeat.comSummit Therapeutics Shock Move Hits Nasdaq FuturesMay 1, 2026 | kalkinemedia.comKSummit Therapeutics falls after update on Akeso-partnered lung cancer trialMay 1, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Time to Sell?May 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKNSA, ASND, BBIO, and SMMT Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$247.05 -0.46 (-0.19%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$247.18 +0.13 (+0.05%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.BridgeBio Pharma NASDAQ:BBIO$69.12 -1.16 (-1.65%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$67.88 -1.24 (-1.80%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$53.24 -0.41 (-0.76%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$53.14 -0.10 (-0.19%) As of 05/22/2026 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Summit Therapeutics NASDAQ:SMMT$16.62 -0.85 (-4.87%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$16.74 +0.12 (+0.73%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
